Diffuse large B cell lymphoma in rheumatoid arthritis express polyreactive and autoreactive BCRs binding protein modifications
4 affiliations
- 1Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, L8:04, Visionsgatan 18, Stockholm, 17176 Sweden
- 2Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
- 3Department of Otorhinolaryngology, Sophiahemmet Hospital, Stockholm, Sweden
- 4Department of Medical Sciences, Rheumatology Uppsala University, Uppsala, Sweden
Abstract
Background: An important risk factor for diffuse large B-cell lymphoma (DLBCL) development in patients with rheumatoid arthritis (RA) is high cumulated disease activity. B cell intrinsic factors and autoimmune processes may contribute, and we hypothesize that BCR autoreactivity may drive lymphomagenesis and/or lymphoma cell survival. RA is primarily associated with anti-citrullinated protein autoantibodies but patients can also have other anti-modified protein autoantibodies, e.g. towards malondialdehyde acetaldehyde (MDA/MAA) adducts which correlate with disease activity and inflammation. Here, we investigated DLBCL properties from RA patients with concurrent lymphoma by B-cell receptor (BCR) next generation sequencing and re-expression.
Methods: In total 22 RA-DLBCL patients were included from the Swedish AUTO-LYMPHOMA cohort. Tumour DNA was extracted from fixed tissues and full length VH/VL fragments were amplified by multiplex PCR and sequenced using Illumina. Computational analysis assessed clonal variations. Dominating sequences were synthesized and expressed as recombinant monoclonal antibodies for antigen binding analysis.
Results: Complete VH/VL lymphoma tissue sequences were generated from nine RA-DLBCL patients. Clonotype diversity within the tumour was generally low and the dominant paired heavy and light chain BCR sequences were obtained for six patients. For three patients, amino acid variations in the DLBCL clonotype indicated intra-clonal evolution. Two of six patients had tumour BCRs with few VH and VL somatic hypermutations (≤ 5 mismatches) while three had high mutations (> 15 VH or VL mismatches). No bias in VH/VL usage was detected. Six lymphoma BCRs from five patients were expressed as recombinant monoclonal antibodies and their binding to autoantigens was assessed by ELISA and a solid-phase microarray (> 400 antigens). All patient-derived lymphoma BCRs were CCP2 negative, but five bound MDA/MAA-protein. Three of these displayed polyreactive binding by in-house assays of which two further displayed strikingly broad polyreactivity on the antigen array. Importantly, for one patient, the lymphoma BCR had high specificity to MDA/MAA-protein, and another patient DLBCL-BCR had binding only to methylated protein.
Conclusions: The data suggest a possible link between polyreactivity and anti-MDA/MAA autoreactivity in RA-DLBCL lymphomagenesis. We hypothesize that high inflammation burden could increase antigen load which may trigger polyreactive and modified-protein B cell responses and/or maintain lymphoma cell survival.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13075-026-03937-0.
Related
- Intravascular large B-cell lymphoma presenting as unilateral lymphedema in a patient with rheumatoid arthritis and sarcoidosis : A case report
- P045 Occult large vessel vasculitis in a patient with apparent rheumatoid arthritis
- The Bidirectional Relationship Between Rheumatoid Arthritis and Periodontitis: Current Evidence and Clinical Implications
- P080 Relapsing giant cell arteritis: atypical relapses, pre-existing osteoporosis and emerging rheumatoid arthritis
- Granulomatous Interstitial Nephritis Associated With Adalimumab Therapy in a Patient With Rheumatoid Arthritis: A Case Report
BibTeX
@article{euler2026diffuse,
title = {{Diffuse large B cell lymphoma in rheumatoid arthritis express polyreactive and autoreactive BCRs binding protein modifications}},
author = {Nora Euler and Ana Cristina Gonzalez-Sanchez and Elizabeth Clark and Hedvig Mildner and Marina Galesic and Andrea Kemp and Mattias Jangard and Erik Hellbacher and Nils Landegren and Lina Marcela Diaz-Gallo and Lars Klareskog and Vivianne Malmström and Eva Baecklund and Caroline Grönwall},
journal = {Arthritis Research \& Therapy},
year = {2026},
month = oct,
doi = {10.1186/s13075-026-03937-0},
url = {https://doi.org/10.1186/s13075-026-03937-0},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Diffuse large B cell lymphoma in rheumatoid arthritis express polyreactive and autoreactive BCRs binding protein modifications
AU - Nora Euler
AU - Ana Cristina Gonzalez-Sanchez
AU - Elizabeth Clark
AU - Hedvig Mildner
AU - Marina Galesic
AU - Andrea Kemp
AU - Mattias Jangard
AU - Erik Hellbacher
AU - Nils Landegren
AU - Lina Marcela Diaz-Gallo
AU - Lars Klareskog
AU - Vivianne Malmström
AU - Eva Baecklund
AU - Caroline Grönwall
PY - 2026
DA - 2026/10/27
JO - Arthritis Research & Therapy
DO - 10.1186/s13075-026-03937-0
UR - https://doi.org/10.1186/s13075-026-03937-0
AB - Background: An important risk factor for diffuse large B-cell lymphoma (DLBCL) development in patients with rheumatoid arthritis (RA) is high cumulated disease activity. B cell intrinsic factors and autoimmune processes may contribute, and we hypothesize that BCR autoreactivity may drive lymphomagenesis and/or lymphoma cell survival. RA is primarily associated with anti-citrullinated protein autoantibodies but patients can also have other anti-modified protein autoantibodies, e.g. towards malondialdehyde acetaldehyde (MDA/MAA) adducts which correlate with disease activity and inflammation. Here, we investigated DLBCL properties from RA patients with concurrent lymphoma by B-cell receptor (BCR) next generation sequencing and re-expression. Methods: In total 22 RA-DLBCL patients were included from the Swedish AUTO-LYMPHOMA cohort. Tumour DNA was extracted from fixed tissues and full length VH/VL fragments were amplified by multiplex PCR and sequenced using Illumina. Computational analysis assessed clonal variations. Dominating sequences were synthesized and expressed as recombinant monoclonal antibodies for antigen binding analysis. Results: Complete VH/VL lymphoma tissue sequences were generated from nine RA-DLBCL patients. Clonotype diversity within the tumour was generally low and the dominant paired heavy and light chain BCR sequences were obtained for six patients. For three patients, amino acid variations in the DLBCL clonotype indicated intra-clonal evolution. Two of six patients had tumour BCRs with few VH and VL somatic hypermutations (≤ 5 mismatches) while three had high mutations (> 15 VH or VL mismatches). No bias in VH/VL usage was detected. Six lymphoma BCRs from five patients were expressed as recombinant monoclonal antibodies and their binding to autoantigens was assessed by ELISA and a solid-phase microarray (> 400 antigens). All patient-derived lymphoma BCRs were CCP2 negative, but five bound MDA/MAA-protein. Three of these displayed polyreactive binding by in-house assays of which two further displayed strikingly broad polyreactivity on the antigen array. Importantly, for one patient, the lymphoma BCR had high specificity to MDA/MAA-protein, and another patient DLBCL-BCR had binding only to methylated protein. Conclusions: The data suggest a possible link between polyreactivity and anti-MDA/MAA autoreactivity in RA-DLBCL lymphomagenesis. We hypothesize that high inflammation burden could increase antigen load which may trigger polyreactive and modified-protein B cell responses and/or maintain lymphoma cell survival. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13075-026-03937-0.
SN - 1478-6354
SN - 1478-6362
ER -